On Thursday, March 2, 2023, Cooper Companies, a major producer of contact lenses and medical equipment, is scheduled to release its financial results. The business has had a successful year, and its stock price has been steadily rising. Recent market signs, however, indicate that the stock may be changing from an upward to a bearish trend.
The 10-day RSI Indicator for COO moved out of overbought territory on February 03, 2023, which is a signal that the stock is potentially entering a bearish phase. This means that traders may want to consider selling the stock or buying put options to protect themselves from potential losses.
Tickeron's A.I.dvisor analyzed 37 instances where the RSI Indicator moved out of the overbought zone, and found that in 22 of those cases, the stock price moved lower in the days that followed. This puts the odds of a move down at 59%, which is a significant risk for investors.
Investors should generally consider the earnings announcement from Cooper Companies cautiously. Even if the company has a proven track record of success, current market signs point to a potential danger of a decline in the near term.
COO saw its Momentum Indicator move below the 0 level on December 06, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In of the 87 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for COO turned negative on December 09, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
COO moved below its 50-day moving average on December 05, 2024 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for COO entered a downward trend on December 10, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where COO's RSI Indicator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .
COO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. COO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.563) is normal, around the industry mean (23.246). P/E Ratio (68.089) is within average values for comparable stocks, (83.568). Projected Growth (PEG Ratio) (12.258) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (43.227).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of medical devices
Industry MedicalSpecialties